Dr. Thomas Pudlarz highlights a new experimental targeted therapy, daraxim, as a significant advancement in treating pancreatic cancer. The therapy aims to improve both survival rates and quality of life for patients with advanced disease.

Oliver Farry is pleased to welcome Dr. Thomas Pudlarz, Oncologist and Head of the pancreatic care pathway within the 'Interception' program at the Gustave-Roussy Institute. For decades, pancreatic cancer has remained one of oncology's most formidable challenges. Despite major advances in immunotherapy and precision medicine, treatment for pancreatic cancer remains elusive. The emergence of daraxim, an experimental targeted therapy is "one of the first improvements in many years" for a disease th...